Drug intelligence / Profile preview

AC-082

Development stage: Unknown
Lead developer: Idorsia
Modality: Small Molecules
Administration: Oral

Overview

AC-082 is a small molecule drug initially developed by Actelion Pharmaceuticals. It has been investigated for the treatment of nervous system diseases, with its highest global R&D status listed as pending. The drug has undergone at least one Phase 1 clinical trial to assess its safety, tolerability, pharmacokinetics (including food effect), and pharmacodynamics in healthy subjects when administered orally. The specific mechanism of action and molecular targets for AC-082 have not been disclosed in public sources[1].

Beyond the preview

Go deeper on AC-082.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AC-082.

Explore the full profile